Generex Biotechnology has received a new patent for its buccal drug delivery platform technologies from the Canadian Intellectual Property Office.
Generex claims that the new Canadian Patent no. 2,354,148 titled Aerosol Formulations for Buccal and Pulmonary Application increases the number of issued patents related to the its buccal drug delivery platform technologies to 162 and a total of 101 patent applications in the field remain pending.
Generex chief operating officer Rose Perri said they continue to augment the breadth and depth of the intellectual property protection for their drug delivery platform.
"As we continue to pursue the platform’s commercialization opportunities for insulin and other active pharmaceutical ingredients," Perri said.